Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Down-regulated HHLA2 enhances neoadjuvant immunotherapy efficacy in patients with non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD)

Fig. 5

NSCLC with COPD was featured by CD8+CD103+TRM enrichment. (A) Immune infiltration analysis in NSCLC with COPD versus NSCLC without COPD via CIBERSORT based on TCGA data. (B) Representative flow cytometry chart of CD8+CD103+TRM in NSCLC with COPD versus NSCLC without COPD. (C) Representative flow cytometry chart of GZMB, IFNG, PD1 among CD8+CD103+TRM in NSCLC with COPD versus NSCLC without COPD. (D) Statistical maps of CD8+CD103+TRM proportion and function in NSCLC with COPD versus NSCLC without COPD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001

Back to article page